Eckman Peter M, Thorsgard Marit, Maurer David, Kim Youngki, Alloway Rita R, Woodle E Steve
Department of Medicine, University of Minnesota, USA.
Clin Transpl. 2009:475-8.
This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.
该经验表明，基于硼替佐米的治疗方案为一名成年心脏移植受者的晚期难治性急性细胞性排斥反应（AMR）提供了有效的治疗，且耐受性良好。尽管AMR发作具有难治性，但这一显著积极的经验有力地支持了继续评估硼替佐米在该患者群体中的应用。
